Adipotide

5mg Vial

2 September 2026Updated 2 September 2026

Adipotide

Overview Research0 Mechanism Protocols Safety

Discussions

This is Premium content Premium

Create a free account, then upgrade to Premium or Lifetime to unlock the full research article, mechanism of action, results timeline, dosing protocol, and dose calculator for Adipotide.

Create free account Member login

Full range of benefits for Adipotide

Targets prohibitin on white adipose vasculature (mechanism)

Induces apoptosis of adipose blood vessels in preclinical studies

Reduces white adipose tissue mass in animal models

Associated with rapid weight loss in obese animal studies

Improves glucose tolerance and insulin sensitivity in animals

Reduces circulating adipokines (e.g., leptin) in some studies

Serves as a research tool for vasculature-targeted obesity therapies

Provides proof-of-concept for targeting adipose vasculature to alter metabolism

This peptide's combination-safety and interaction data below always stays visible, regardless of membership.

Warning

Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.

Peptide Interactions

// 16 known interactions

Synergistic(4)Compatible(4)Monitor(4)Avoid(4)

Not recommended for concurrent use

Pregnancy and breastfeeding

Safety in pregnancy and lactation has not been established; avoid use unless potential maternal benefit justifies potential fetal or neonatal risk.

Pre-existing chronic kidney disease (CKD stage ≥3)

History of significant renal impairment warrants careful risk–benefit assessment, heightened monitoring or avoidance because of reported renal tubular effects with adipotide.

Concurrent cytotoxic or vascular-targeting anticancer agents

Potential for additive vascular or endothelial toxicity exists; evaluate risk–benefit and monitor for systemic vascular adverse events when combined.

Anticoagulants and antiplatelet agents (e.g., warfarin, direct oral anticoagulants, clopidogrel)

Given adipotide's adipose vascular disruption, exercise caution and assess bleeding risk and need for intensified clinical monitoring before co-administration.

All interaction categories

Synergistic (4)

GLP-1 receptor agonists (e.g., semaglutide, liraglutide): May produce additive weight loss and metabolic benefit through complementary mechanisms (central appetite suppression versus adipose vascular disruption), potentially enhancing efficacy but requiring monitoring for excessive weight reduction.
SGLT2 inhibitors (e.g., empagliflozin, canagliflozin): Promote caloric loss via glycosuria and can augment adipotide-induced fat mass reduction, providing potentially synergistic improvements in weight and glycemic control.
Orlistat: Reduces intestinal fat absorption and can complement adipotide's adipose-targeted mechanism to increase net loss of adipose tissue.
Metformin: Insulin-sensitizing and modestly weight‑lowering effects may synergize with adipotide to improve metabolic endpoints such as insulin resistance and glycaemia.

Compatible (4)

Atorvastatin (HMG-CoA reductase inhibitors): No known pharmacokinetic or pharmacodynamic interaction with adipotide; lipid-lowering therapy can generally be continued without adjustment.
Omeprazole (proton pump inhibitors): Systemic acid-suppressing therapy is not expected to interact with systemically administered peptide adipotide and is generally compatible.
Levothyroxine (thyroid hormone replacement): Thyroid hormone replacement has no established interaction with adipotide; continue usual thyroid function monitoring.
Topical therapies with minimal systemic absorption (e.g., topical NSAIDs, emollients): Limited systemic exposure makes clinically significant interaction with systemic adipotide unlikely.

Monitor (4)

Nonsteroidal anti-inflammatory drugs (NSAIDs, e.g., ibuprofen, naproxen): Concurrent use may increase risk of renal adverse effects; monitor serum creatinine, urine output and urinalysis during co-administration.
ACE inhibitors / ARBs (e.g., lisinopril, losartan): Because adipotide has been associated with renal tubular changes, monitor renal function and electrolytes and adjust antihypertensive dosing as needed.
Diuretics (loop and thiazide diuretics, e.g., furosemide, hydrochlorothiazide): Monitor volume status, renal function and electrolytes since combined effects can unmask or worsen renal impairment or electrolyte disturbances.
Aminoglycosides and other known nephrotoxins (e.g., gentamicin, amphotericin B, radiographic contrast agents): Concurrent exposure may increase risk of nephrotoxicity; perform close monitoring of renal biomarkers and consider alternative agents where possible.

Avoid (4)

Pregnancy and breastfeeding: Safety in pregnancy and lactation has not been established; avoid use unless potential maternal benefit justifies potential fetal or neonatal risk.
Pre-existing chronic kidney disease (CKD stage ≥3): History of significant renal impairment warrants careful risk–benefit assessment, heightened monitoring or avoidance because of reported renal tubular effects with adipotide.
Concurrent cytotoxic or vascular-targeting anticancer agents: Potential for additive vascular or endothelial toxicity exists; evaluate risk–benefit and monitor for systemic vascular adverse events when combined.
Anticoagulants and antiplatelet agents (e.g., warfarin, direct oral anticoagulants, clopidogrel): Given adipotide's adipose vascular disruption, exercise caution and assess bleeding risk and need for intensified clinical monitoring before co-administration.